Blood Purification Studies in the ICU: What Endpoints Should We Use?

被引:4
|
作者
Forni, Lui G. [1 ,2 ,3 ]
机构
[1] Royal Surrey Hosp, Dept Crit Care, Guildford, Surrey, England
[2] Royal Surrey Hosp, SPACeR Grp, Surrey Perioperat Anaesthesia & Crit Care Collabo, Guildford, Surrey, England
[3] Univ Surrey, Fac Hlth Sci, Dept Clin & Expt Med, Guildford, Surrey, England
关键词
Acute kidney injury; Kidney replacement therapy; Blood purification techniques; Randomized controlled trials; Heterogeneity of treatment effect; Trial sequential analysis; POLYMYXIN-B HEMOPERFUSION; CLINICAL-TRIALS; SEPTIC SHOCK; SEPSIS; MORTALITY; CARE; PREDICTION; MEDICINE; PATIENT; ARDS;
D O I
10.1159/000523761
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The potential for treatment of the critically ill using blood purification techniques has been discussed for several decades. However, since the first attempts at applying extracorporeal techniques to patients with sepsis were described, there has been considerable hesitancy towards the widespread adoption of such methods, given the lack of mortality benefit observed and indeed the paucity of randomized controlled studies. However, this is not unique so far as studies on the critically ill are concerned where there is a dearth of studies providing a positive finding to influence clinical practice. Consequently, as well as targeted patient selection, it is perhaps time to consider endpoints other than mortality in studies on the critically ill, particularly in blood purification studies where, to-date, such heterogeneous groups of patients have been studied.
引用
收藏
页码:990 / 996
页数:7
相关论文
共 50 条
  • [31] Circadian Rhythms in Bacterial Sepsis Pathology: What We Know and What We Should Know
    Mul Fedele, Malena Lis
    Senna, Camila Agustina
    Aiello, Ignacio
    Golombek, Diego Andres
    Paladino, Natalia
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2021, 11
  • [32] Teamwork in the ICU-Do We Practice What We Preach? Foreword
    Parker, Margaret M.
    CRITICAL CARE MEDICINE, 2016, 44 (02) : 254 - 255
  • [33] Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do?
    Perazella, Mark A.
    Shirali, Anushree C.
    KIDNEY INTERNATIONAL, 2020, 97 (01) : 62 - 74
  • [34] Should we increase the ratio of plasma/platelets to red blood cells in massive transfusion: what is the evidence?
    Phan, H. H.
    Wisner, D. H.
    VOX SANGUINIS, 2010, 98 (03) : 395 - 402
  • [35] Postsurgical Recovery and Long-Term Outcomes: What Should We Be Measuring?
    Hogg, Rosemary M. G.
    O'Donnell, Ciara M.
    CURRENT ANESTHESIOLOGY REPORTS, 2024, 14 (01) : 42 - 49
  • [36] What should we expect in a prognosis study in 2012?
    Hachamovitch, Rory
    JOURNAL OF NUCLEAR CARDIOLOGY, 2012, 19 (05) : 883 - 886
  • [37] Idiopathic Condylar Resorption What Should We Do?
    Mercuri, Louis G.
    Handelman, Chester S.
    ORAL AND MAXILLOFACIAL SURGERY CLINICS OF NORTH AMERICA, 2020, 32 (01) : 105 - +
  • [38] Extracorporeal Life Support: What Should We Be Targeting?*
    Park, Pauline K.
    CRITICAL CARE MEDICINE, 2017, 45 (12) : 2106 - 2107
  • [39] Men's Health: What Should We Know?
    Kim, Sae Woong
    WORLD JOURNAL OF MENS HEALTH, 2015, 33 (02) : 45 - 49
  • [40] Burnout in the ICU-What Do We Do Now?
    Vernon, Donald D.
    PEDIATRIC CRITICAL CARE MEDICINE, 2017, 18 (07) : 725 - 726